How to Group Multiple Models for Overseas Registration of Sterile Consumables?

Executive Summary

Grouping multiple models for overseas registration of sterile consumables is essential for cost efficiency, but it is also the stage where misunderstandings are most likely. Companies must first determine whether the target country or region regulates the product as a medical device, and then determine its risk classification based on intended use, contact site, and contact duration, so as to select the appropriate registration pathway. On this basis, systematically review existing regulatory filings and documentation—such as NMPA, CE, FDA, ISO 13485, or MDSAP—and assess what can be reused directly and what needs local adaptation. Technical documents, biocompatibility testing, sterilization validation, risk management, clinical evaluation or clinical evidence, labels and instructions, and local agent or authorized representative arrangements must be re-evaluated according to the target market's requirements.

Group submission is not simply merging models. The applicant must demonstrate that the models in the same group share sufficient similarity in basic principle, structural composition, manufacturing process, intended use, and key performance, and that any differences do not affect safety or effectiveness. Common risks include overly broad grouping leading to reviewer objections, insufficient evidence leading to requests for correction, change of agent causing loss of certificate control, and failure to file post-market changes in a timely manner. To mitigate these, plan grouping strategies early, build a core technical document library, establish a model-difference comparison matrix, and assign a dedicated person to update and maintain multi-country registration files.

Applicable Scenarios and Core Questions

Sterile consumable manufacturers often have multiple models or specifications, such as syringes, infusion sets, catheters, or procedure kits that differ in length, diameter, connector type, or packaging format. The key question is whether to file each model individually, submit all as one registration unit, or split them into several groups.

This issue is essentially about aligning the registration unit definition with the actual review logic. Different countries have different definitions of a “family” or “series” of products and require different levels of evidence to prove equivalence. If the group is too broad, reviewers may require extensive difference analysis or extra testing; if too narrow, costs and timelines multiply unnecessarily.

Some manufacturers use a “one model, one certificate” approach, but this is often cost-prohibitive in GHWP member states, Southeast Asia, the Middle East, and Latin America. Local regulators generally encourage series product management. Therefore, mastering how to group models and organize evidence is critical to the overall project timeline and budget.

Registration Determination Logic

Confirm Medical Device Classification

First, confirm whether the product falls under medical device regulations in the target country. Most sterile consumables are medical devices, but some are regulated as pharmaceuticals or combination products—for example, drug-coated catheters or pre-filled syringes. Review the country's regulatory list or consult a local agent to clarify the correct regulatory classification.

Determine Risk Class and Registration Pathway

Sterile consumables are usually single-use and come into contact with the human body or blood, so most are classified as medium or high risk. Under EU MDR they may be Class IIa or IIb; in the US they may be Class II or III; GHWP member states follow GHTF-based classification rules. The risk class affects technical documentation requirements, review depth, and the flexibility of grouping.

Assess Existing Documentation

If the company already holds NMPA registration, CE certificates, FDA 510(k) or PMA, ISO 13485, or MDSAP, systematically assess whether the product descriptions, performance verification, sterilization validation, risk management, clinical data, and labels cover the models intended for submission.

If some models have specifications or performance that fall outside the existing evidence, they cannot be simply merged. For example, if a catheter length change significantly affects fluid performance, new flow testing or animal studies may be required.

Local Agent and Post-Market Requirements

Many countries require a local agent or authorized representative. The agent is responsible for adverse event collection, regulatory communication, and maintenance of technical files. When multiple models are grouped under one certificate, the agent must be able to identify the exact models covered and manage changes and renewals during the certificate's validity period.

Documentation and Evidence

Core documentation for multi-model group submission includes:

• Product description and intended use
• Basic principles and structural composition
• Model difference comparison
• Manufacturing process and sterilization method
• Performance verification reports
• Biocompatibility testing
• Risk management reports
• Clinical evaluation or clinical evidence
• Labels and instructions for use
• Packaging validation and stability data

The model difference comparison table is critical. It must list parameter changes, material changes, dimensional differences, and functional differences, and analyze whether these affect safety, effectiveness, or risk management conclusions. The table should convince reviewers that the models belong to the same technical platform with minor clinical or operational variations.

Reusable evidence—such as basic biocompatibility testing, sterilization validation, and packaging integrity testing—can be shared if the outcomes remain applicable. However, if materials change or surface area changes significantly, additional testing may be necessary, including worst-case sample testing.

Localized documents include labels, instructions, and packaging language and symbols. Some countries require local agents to draft or review these, and translation notarization may be required.

Risk management documentation per ISO 14971 must cover all models. Risk analysis should identify model-specific risks and describe control measures. For clinical evidence, if data come from a representative model, the rationale for extrapolation to other models must be explained.

Quality system documents demonstrating that production environment, process control, and sterilization control apply to all models must be prepared. Some countries may conduct on-site inspections or require QMS certificates.

Common Mistakes

• Grouping models with the same basic principle but different intended uses, such as some for intravascular use and others for non-vascular use, making unified review impossible.
• Overly broad grouping that focuses only on structural similarity but ignores major differences in sterilization method, material, or performance parameters.
• Overly narrow grouping, leading to unnecessary duplicate testing and review fees.
• Failing to prepare a model difference comparison table, forcing reviewers to ask repeated clarification requests.
• Neglecting worst-case sample selection, so the tested samples do not represent the highest-risk model in the group.
• Losing control of certificates and registration files after a change in local agent, blocking renewal or amendments.
• Failing to assess whether a post-market design change or new model requires an update to the certificate or an additional application.
• Directly translating evidence from another country without considering local requirements for clinical data, test methods, and technical standards.

Pre-submission Checklist

• Develop a product matrix listing all models, specifications, materials, intended uses, and sterilization methods.
• Review target country regulatory requirements, determine risk class and registration pathway, and obtain official or agent confirmation.
• Evaluate reusability of existing NMPA, CE, FDA, ISO 13485, and MDSAP documents, and create a coverage matrix.
• Complete a model difference comparison analysis, with review by R&D and regulatory personnel.
• Supplement testing or validation related to those differences, ensuring worst-case samples are included.
• Prepare localized labels and instructions for use, and submit them to the agent or consultant for review.
• Appoint a local agent or authorized representative and sign a service agreement that defines certificate management and post-market obligations.
• Set up a registration file management system to record model lists, change history, and renewal deadlines for each certificate.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment in multi-model group submission is to assume that “similar appearance” or “same structure” is enough to group models, while ignoring the target country's substantive definition of a “series product.” The key is not whether model names are similar, but whether differences can be covered by existing evidence.

We recommend conducting a “registrability assessment” early in the project—a two-week exercise that builds the product difference matrix and analyzes existing documentation coverage. Even if this costs a significant amount, it prevents far larger losses from review delays and deficiency letters. On the documentation side, verification reports, risk management files, and quality system documents are often reusable, but labels, instructions, agent letters, and locally required certificates must be localized.

The local agent or authorized representative plays a pivotal role. After grouping multiple models, there is usually one certificate but a long list of covered models. If the agent changes frequently, or if certificate control is unclear, renewal, amendment, or regulatory inspections can become high-risk. Establish a regular communication mechanism with the agent and retain original and signed versions of all registration files.

For multi-country registration, the core strategy is “one core technical document set, local adaptation for each country.” Build a master technical file covering all models, then extract the relevant content and format according to each target country's requirements. This reduces duplicate work and prevents file-version-related deficiency risks. Note that different countries may emphasize different points—some focus on sterility, some on clinical data, some on label wording. Prepare accordingly before the first submission.

Common Follow-up Questions

How many models can be included in one registration unit?

There is no universal legal upper limit, but too many models significantly increase review difficulty and evidence burden. In practice, models in the same group should be highly consistent in structural principle, intended use, and key performance, and differences should not create new safety risks. A single submission of 5 to 20 models is often feasible. If there are more than 50 or even 100, reviewers may require the group to be split into subgroups.

What are the common principles for selecting representative models?

Representative models are usually those representing the worst case or the most complex configuration, such as the largest size, thinnest wall, highest flow rate, or highest-risk material. The goal is to ensure test results cover all other models in the group. If differences involve different materials or functions, multiple representative models may be needed, each with corresponding tests.

If a new model is added after market approval, does the certificate need to be updated?

Yes. Most countries require a new model to be treated as a design change or model extension of the certified product, necessitating a change application or additional registration. If the new model differs significantly from the models already covered, new technical documents or supplementary testing may be required. Always consult the local agent before launch to confirm the change type and filing pathway, and avoid unauthorized commercialization.